Yıl: 2022 Cilt: 56 Sayı: 1 Sayfa Aralığı: 34 - 38 Metin Dili: İngilizce DOI: 10.4274/turkderm.galenos.2021.2904 İndeks Tarihi: 16-06-2022

Drug eruption: A mimicker of Coronavirus disease-2019 rash

Öz:
Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infections can be associated with several cutaneous lesions, among which maculopapular rash is the most common. A maculopapular rash can also be induced by medications used for Coronavirus disease-2019 (COVID-19) treatment. The distinction between viral rash and drug eruption may be difficult especially in case of several medication use for COVID-19. Thus, this study aimed to describe cutaneous manifestations in six patients with COVID-19 and highlight clues for distinguishing SARS-CoV-2-related rash and drug eruption. Between March and June 2020, 1,492 patients were hospitalized for COVID-19 and treated with hydroxychloroquine in Marmara University Hospital. Among them, six cases were consulted for possible COVID-19-related rash or drug reaction. Hydroxychloroquine was given as monotherapy in one patient. All six patients developed an erythematous, symmetrical, and maculopapular eruption that mainly affected the trunk, axilla, and genitocrural region, 5-21 days after the onset of COVID-19 symptoms. Five patients developed rash in 4-11 days after treatment completion. Pruritus was severe. All were treated with topical corticosteroids and oral antihistamines, which provided partial relief. The resolution of the eruption was typically slow, which took a few weeks. A long period between the COVID-19 symptoms and the eruption, as well as slow recovery, is in favor of drug eruption. The effects of co-existent viral infection, a well-known promoting drug eruption factor, in facilitating adverse drug reaction in patients with COVID-19 needs further observations and research
Anahtar Kelime:

İlaç erüpsiyonu: Koronavirüs hastalığı-2019 döküntüsünün bir taklitçisi

Öz:
Şiddetli akut solunum yolu sendromu-koronavirüs-2 (SARS-CoV-2) enfeksiyonu çeşitli kutanöz lezyonlara sebep olabilir. Bunlar içerisinde en sık görüleni makülopapüler döküntüdür. Makülopapüler döküntü, Koronavirüs hastalığı-2019 (COVİD-19) hastalığının tedavisi için kullanılan ilaçlarla da indüklenebilir. COVİD-19 hastalığı için çeşitli ilaçların kullanıldığı durumlarda, viral döküntü ile ilaç erüpsiyonu arasında ayırım yapmak zor olabilir. Bu çalışmanın amacı, COVİD-19 olan altı hastada kutanöz bulguları tanımlamak ve SARS-CoV-2 ile ilişkili döküntü ile ilaç erüpsiyonunu ayırt etmek için ipuçlarını vurgulamaktır. Mart ve Haziran 2020 arasında, Marmara Üniversitesi Hastanesi’ne yatırılarak hidroksiklorokin ile tedavi edilen 1.492 COVİD-19 olgusu içinde, olası COVİD-19 döküntüsü veya ilaç reaksiyonu olan altı tanesi konsülte edildi. Bir hastada hidroksiklorokin monoterapi olarak verilmişti. Altı hastanın tümünde, COVİD-19 semptomlarının başlangıcından 5 ile 21 gün sonra, başlıca gövdeyi, aksillayı ve genitokrural bölgeyi etkileyen, eritematöz, simetrik, makülopapüler bir erüpsiyon gelişmişti. Beş hastada, tedavinin tamamlanmasından 4 ile 11 gün sonra döküntü ortaya çıkmıştı. Kaşıntı şiddetliydi. Hastaların tümü, topikal kortikosteroidler ve oral antihistaminiklerle kısmi düzelme gösterdi. Erüpsiyonun düzelmesi tipik olarak yavaş olup birkaç hafta sürdü. COVİD-19 semptomları ile erüpsiyonun ortaya çıkışı arasındaki zamanın uzun olması ve yavaş düzelme, ilaç erüpsiyonu lehinedir. Eşlik eden viral enfeksiyonun ilaç erüpsiyonu ortaya çıkışını kolaylaştırıcı bir faktör olduğu iyi bilinmektedir. COVİD-19 hastalarında da viral enfeksiyon varlığında ilaç reaksiyonu ortaya çıkışının kolaylaşabileceği konusu, ileri gözlemler ve araştırmalarla gösterilmelidir
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Olgu Sunumu Erişim Türü: Erişime Açık
  • 1. World Health Organization. Naming the coronavirus disease (COVID-19) and the virus that causes it. Available at: https://www.who.int/emergencies/ diseases/novel-coronavirus-2019/technical-guidance/naming-the- coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it
  • 2. WHO Coronavirus Disease (COVID-19) Dashboard. (access: 31 May 2021). Available at: https://www.who.int/emergencies/diseases/novel- coronavirus-2019/
  • 3. Letter revoking EUA for chloroquine phosphate and hydroxychloroquine sulfate. Available at: https://www.fda.gov/media/138945/download.
  • 4. https://covid19.saglik.gov.tr/Eklenti/40719/0/covid-19rehberieriskinhastay onetimivetedavipdf.pdf
  • 5. Ardern-Jones MR, Friedmann PS: Skin manifestations of drug allergy. Br J Clin Pharmacol 2011;71:672-83.
  • 6. Salido M, Joven B, D’Cruz DP, Khamashta MA, Hughes GRV: Increased cutaneous reactions to hydroxychloroquine (Plaquenil) possibly associated with formulation change: comment on the letter by Alarcón. Arthritis Rheum 2002;46:3392-6.
  • 7. Sharma AN, Mesinkovska NA, Paravar T: Characterizing the adverse dermatologic effects of hydroxychloroquine: a systematic review. J Am Acad Dermatol 2020;83:563-78.
  • 8. Galván Casas C, Català A, Carretero Hernández G, et al.: Classification of the cutaneous manifestations of COVID-19: A rapid prospective nationwide consensus study in Spain with 375 cases. Br J Dermatol 2020;183:71-7.
  • 9. Freeman EE, McMahon DE, Lipoff JB, et al.: The spectrum of COVID-19 associated dermatologic manifestations: an international registry of 716 patients from 31 countries. J Am Acad Dermatol 2020;83:1118-29.
  • 10. de Masson A, Bouaziz J, Sulimovic L, et al.: Chilblains is a common cutaneous finding during the COVID-19 pandemic: a retrospective nationwide study from France. J Am Acad Dermatol 2020;83:667-70.
  • 11. Hoetzenecker W, Nägeli M, Mehra ET, et al.: Adverse cutaneous drug eruptions: current understanding. Semin Immunopathol 2016;38:75-86.
  • 12. Tanaka E, Taniguchi A, Urano W, Yamanaka H, Kamatani N: Pharmacogenetics of disease-modifying anti-rheumatic drugs. Best Pract Res Clin Rheumatol 2004;18:233-47.
  • 13. Munster T, Gibbs JP, Shen D, et al.: Hydroxychloroquine concentration- response relationships in patients with rheumatoid arthritis. Arthritis Rheum 2002;46:1460-9.
  • 14. Nobari N, Seirafianpour F, Mashayekhi F, Goodarzi A: A systematic review on treatment-related mucocutaneous reactions in COVID-19 patients. Dermatol Ther 2021;34:e14662.
  • 15. Schrezenmeier E, Dörner T: Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol 2020;16:155-66.
  • 16. I Doña, E Barrionuevo, N Blanca-Lopez, et al.: Trends in hypersensitivity drug reactions: More drugs, more response patterns, more heterogeneity. J Investig Allergol Clin Immunol 2014;24:143-53.
  • 17. Phillips EJ, Bigliardi P, Bircher AJ, et al.: Controversies in drug allergy: Testing for delayed reactions. J Allergy Clin Immunol 2019;143:66-73.
  • 18. Soria A, Barbaud A, Assier H, et al.: Cutaneous adverse drug reactions with antimalarials and allergological skin tests. Dermatology 2015;231:353-9.
  • 19. Schnyder B, Brockow K: Pathogenesis of drug allergy-- current concepts and recent insights. Clin Exp Allergy 2015;45:1376-83.
  • 20. Balakirski G, Merk HF: Cutaneous allergic drug reactions: Update on pathophysiology, diagnostic procedures and differential diagnosic. Cutan Ocul Toxicol 2017;36:307-16.
  • 21. Vaninov N: In the eye of the COVID-19 cytokine storm. Nat Rev Immunol 2020;20:277
APA Ergun T, ergenç i, SEVEN S, SEÇKİN D, ÖZER E, AKTAŞ M, TÜKENMEZ TİGEN E (2022). Drug eruption: A mimicker of Coronavirus disease-2019 rash. , 34 - 38. 10.4274/turkderm.galenos.2021.2904
Chicago Ergun Tulin,ergenç ilkay,SEVEN Seda,SEÇKİN Dilek,ÖZER Elif Cömert,AKTAŞ Meryem,TÜKENMEZ TİGEN Elif Drug eruption: A mimicker of Coronavirus disease-2019 rash. (2022): 34 - 38. 10.4274/turkderm.galenos.2021.2904
MLA Ergun Tulin,ergenç ilkay,SEVEN Seda,SEÇKİN Dilek,ÖZER Elif Cömert,AKTAŞ Meryem,TÜKENMEZ TİGEN Elif Drug eruption: A mimicker of Coronavirus disease-2019 rash. , 2022, ss.34 - 38. 10.4274/turkderm.galenos.2021.2904
AMA Ergun T,ergenç i,SEVEN S,SEÇKİN D,ÖZER E,AKTAŞ M,TÜKENMEZ TİGEN E Drug eruption: A mimicker of Coronavirus disease-2019 rash. . 2022; 34 - 38. 10.4274/turkderm.galenos.2021.2904
Vancouver Ergun T,ergenç i,SEVEN S,SEÇKİN D,ÖZER E,AKTAŞ M,TÜKENMEZ TİGEN E Drug eruption: A mimicker of Coronavirus disease-2019 rash. . 2022; 34 - 38. 10.4274/turkderm.galenos.2021.2904
IEEE Ergun T,ergenç i,SEVEN S,SEÇKİN D,ÖZER E,AKTAŞ M,TÜKENMEZ TİGEN E "Drug eruption: A mimicker of Coronavirus disease-2019 rash." , ss.34 - 38, 2022. 10.4274/turkderm.galenos.2021.2904
ISNAD Ergun, Tulin vd. "Drug eruption: A mimicker of Coronavirus disease-2019 rash". (2022), 34-38. https://doi.org/10.4274/turkderm.galenos.2021.2904
APA Ergun T, ergenç i, SEVEN S, SEÇKİN D, ÖZER E, AKTAŞ M, TÜKENMEZ TİGEN E (2022). Drug eruption: A mimicker of Coronavirus disease-2019 rash. Türkderm Türk deri hastalıkları ve frengi arşivi, 56(1), 34 - 38. 10.4274/turkderm.galenos.2021.2904
Chicago Ergun Tulin,ergenç ilkay,SEVEN Seda,SEÇKİN Dilek,ÖZER Elif Cömert,AKTAŞ Meryem,TÜKENMEZ TİGEN Elif Drug eruption: A mimicker of Coronavirus disease-2019 rash. Türkderm Türk deri hastalıkları ve frengi arşivi 56, no.1 (2022): 34 - 38. 10.4274/turkderm.galenos.2021.2904
MLA Ergun Tulin,ergenç ilkay,SEVEN Seda,SEÇKİN Dilek,ÖZER Elif Cömert,AKTAŞ Meryem,TÜKENMEZ TİGEN Elif Drug eruption: A mimicker of Coronavirus disease-2019 rash. Türkderm Türk deri hastalıkları ve frengi arşivi, vol.56, no.1, 2022, ss.34 - 38. 10.4274/turkderm.galenos.2021.2904
AMA Ergun T,ergenç i,SEVEN S,SEÇKİN D,ÖZER E,AKTAŞ M,TÜKENMEZ TİGEN E Drug eruption: A mimicker of Coronavirus disease-2019 rash. Türkderm Türk deri hastalıkları ve frengi arşivi. 2022; 56(1): 34 - 38. 10.4274/turkderm.galenos.2021.2904
Vancouver Ergun T,ergenç i,SEVEN S,SEÇKİN D,ÖZER E,AKTAŞ M,TÜKENMEZ TİGEN E Drug eruption: A mimicker of Coronavirus disease-2019 rash. Türkderm Türk deri hastalıkları ve frengi arşivi. 2022; 56(1): 34 - 38. 10.4274/turkderm.galenos.2021.2904
IEEE Ergun T,ergenç i,SEVEN S,SEÇKİN D,ÖZER E,AKTAŞ M,TÜKENMEZ TİGEN E "Drug eruption: A mimicker of Coronavirus disease-2019 rash." Türkderm Türk deri hastalıkları ve frengi arşivi, 56, ss.34 - 38, 2022. 10.4274/turkderm.galenos.2021.2904
ISNAD Ergun, Tulin vd. "Drug eruption: A mimicker of Coronavirus disease-2019 rash". Türkderm Türk deri hastalıkları ve frengi arşivi 56/1 (2022), 34-38. https://doi.org/10.4274/turkderm.galenos.2021.2904